New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 8, 2014
07:31 EDTSGMO, INSY, DSCO, XLRN, GERN, ARGS, THLD, MDCO, EGRX, ANACPiper Jaffray to hold a symposium
Catalyst Symposium to be held in Boston on July 8.
News For ANAC;ARGS;DSCO;EGRX;GERN;INSY;MDCO;XLRN;SGMO;THLD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 11, 2016
07:17 EDTSGMOLeerink to hold a conference
Subscribe for More Information
February 9, 2016
19:18 EDTSGMOOn The Fly: After Hours Movers
UP AFTER EARNINGS: Limelight Networks (LLNW), up 20%... Akamai Technologies (AKAM), up 15.7%... Marketo (MKTO), up 9.9%... Paycom Software (PAYC), up 13.8%... A10 Networks (ATEN), up 7.3%... Prospect Capital (PSEC), up 8.6%... Nuance Communications (NUAN), up 6.5%... Panera Bread (PNRA), up 2.8%. ALSO HIGHER: Empire District Electric (EDE), up 14.8% after Algonquin Power will acquire the company for $34.00 per share. DOWN AFTER EARNINGS: SolarCity (SCTY), down 32.6%... LeapFrog (LF), down 2%... Orion Energy Systems (OESX), down 23.8%... Seattle Genetics (SGEN), down 3.6%... Sangamo Biosciences (SGMO), down 7.1%... Disney (DIS), down 3.4%... Demandware (DWRE), down 2.6%. ALSO LOWER: Sunrun (RUN) is down 6.9%, Solaredge Technologies (SEDG) is down 6.6%, SunEdison (SUNE) is down 5.9%, Canadian Solar (CSIQ) is down 2.9%, SunPower (SPWR) is down 2.9%, and Tesla (TSLA) is down 2.2% following SolarCity's fourth quarter results.
16:08 EDTSGMOSangamo sees FY16 revenue $20M-$25M, consensus $34.23M
Subscribe for More Information
16:07 EDTSGMOSangamo reports Q4 EPS (20c), consensus (21c)
Subscribe for More Information
06:51 EDTINSYInsys Therapeutics enrolls first patient for Phase II study of CBD
Insys Therapeutics announced that the Company has enrolled the first patient in a Phase II clinical study for the treatment of infantile spasms using its pharmaceutical CBD product candidate.
February 8, 2016
07:06 EDTSGMOSangamo announces FDA clearance of IND application for SB-318
Subscribe for More Information
February 3, 2016
08:33 EDTMDCOThe Medicines Co. names Alexander Denner to board
Subscribe for More Information
February 2, 2016
08:36 EDTSGMOPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
06:58 EDTEGRXEagle Pharmaceuticals begins distribution of Alcohol-Free Docetaxel Injection
Eagle Pharmaceuticals announced the shipment and commercial availability of Alcohol-Free Docetaxel Injection. Docetaxel Injection is approved for the treatment of breast cancer, non-small cell lung cancer, prostate cancer, gastric adenocarcinoma, and head and neck cancer.
February 1, 2016
16:05 EDTDSCODiscovery Labs initiates AEROSURF phase 2b clinical trial
Discovery Labs said that based on the safety and tolerability profile observed to date in the phase 2a clinical program, the company has initiated the AEROSURF phase 2b clinical trial in premature infants 26 to 32 week gestational age receiving nasal continuous positive airway pressure for respiratory distress syndrome. The trial is a multicenter, randomized, controlled study with masked treatment assignment in approximately 240 premature infants and is designed to evaluate the safety and tolerability of aerosolized KL4 surfactant administered in two dose groups, compared to infants receiving nCPAP alone. The following endpoints will be evaluated: time to nCPAP failure, incidence of nCPAP failure and physiological parameters indicating the effectiveness of lung function. The trial is expected to be conducted in up to 60 clinical sites in the United States, Canada, Europe and Latin America. Enrollment is beginning with premature infants 29 to 32 weeks GA, and will include premature infants 26 to 28 weeks GA after completion of the ongoing phase 2a clinical trial in this age group. The xompany anticipates completing enrollment for the phase 2b clinical trial by the end of 2016 and releasing top-line results in the first quarter of 2017. As of December 31, 2015, the xompany had cash and cash equivalents of $38.7M, an amount it anticipates is sufficient to support the AEROSURF phase 2 clinical program and fund operations through Q1 of 2017.
16:03 EDTDSCODiscovery Labs announces resignation of CEO John Cooper
Subscribe for More Information
08:51 EDTMDCOThe Medicines Co. completes divestiture of hemostasis portfolio to Mallinckrodt
Subscribe for More Information
08:14 EDTINSYInsys Therapeutics longer term outlook stable, says RBC Capital
After surveying 40 doctors, including nine who prescribed large amounts of Insys' Subsys, RBC Capital says that payor pushback on the drug is "limited," while 95% of all the doctors surveyed and 89% of the high prescribers "intend to write as many or more Subsys prescriptions this year" as last year. The firm thinks the stock's valuation is attractive following its 61% pullback since July. It trimmed its price target on the stock to $44 from $49 but keeps an Outperform rating. .
07:27 EDTXLRNAcceleron coverage assumed with an Outperform at Oppenheimer
06:51 EDTEGRXEagle Pharmaceuticals granted Fast Track for RYANODEX by FDA
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use